Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells

Mélanie Uguen, Devan J. Shell, Madhushika Silva, Yu Deng, Fengling Li, Magdalena M. Szewczyk, Ka Yang, Yani Zhao, Michael A. Stashko, Jacqueline L. Norris-Drouin, Jarod M. Waybright, Serap Beldar, Justin M. Rectenwald, Angie L. Mordant, Thomas S. Webb, Laura E. Herring, Cheryl H. Arrowsmith, Suzanne Ackloo, Steven P. Gygi, Robert K. McGinty, Dalia Barsyte-Lovejoy, Pengda Liu, Levon Halabelian, Lindsey I. James, Kenneth H. Pearce and Stephen V. Frye

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-57005-3

SETDB1: an emerging target for anticancer drug development

Gustavo Henrique Goulart Trossini, Haifa Hassanie, André Berndt Penteado and Marissa El-Hajje

Future Medicinal Chemistry, 2025, 17, 153
DOI: 10.1080/17568919.2024.2444869

Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer

Bo‐Syong Pan, Cheng‐Yu Lin, Gilbert Aaron Lee and Hui‐Kuan Lin

The Kaohsiung J of Med Scie, 2025, 41
DOI: 10.1002/kjm2.12933

Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer

Jing Peng, Wenhui Liu, Jiaju Tian, Yuncong Shu, Rui Zhao and Yuping Wang

Front. Cell Dev. Biol., 2025, 13
DOI: 10.3389/fcell.2025.1544310